Kaposi Sarcoma
📧 Sign up to get email alerts when something new happens for Kaposi Sarcoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-01-22Clinical Trial Update: Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma [Phase 2]
Phase 2 trial of pembrolizumab plus lenvatinib for previously treated classic Kaposi sarcoma has been withdrawn.
-
EMA withdrawal · 2025-11-27EMA Lapsed: Celdoxome pegylated liposomal (doxorubicin hydrochloride) — Baxter Holding B.V.
EMA notes that the marketing authorization for Celdoxome pegylated liposomal doxorubicin hydrochloride has lapsed, covering breast cancer, o…
-
EMA withdrawal · 2021-01-11EMA Withdrawn: Panretin (alitretinoin) — Eisai GmbH
The EMA has withdrawn Panretin (alitretinoin) from the European market, with Eisai GmbH as the marketing authorization holder, for indicatio…
-
CLINICAL_TRIALS withdrawal · 2017-12-07Clinical Trial Update: Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma [Phase 1, Phase 2]
Clinical trial update shows the early-phase study of ABC294640 (opaganib) in refractory/relapsed diffuse large B-cell lymphoma and Kaposi sa…
-
CLINICAL_TRIALS withdrawal · 2015-07-23Clinical Trial Update: Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma [Phase 2]
Phase 2 trial of the gamma secretase inhibitor PF-03084014 for AIDS-related Kaposi sarcoma has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.